NGOs disappointed with outcome of essential drugs workshop
by Chakravarthi Raghavan
Geneva 11 Apr 2001 -- A WHO-WTO sponsored workshop of experts on ‘Affordable Medicines for Poor Countries’ in Norway ended Wednesday with five leading international NGO participants expressing their disappointment that no real progress had been to bring down prices of essential drugs in developing countries.
The five international non-government groups—Consumer Project on Technology (CPT), Health Action International (HAI), Medecins sans Frontier (MSF), Oxfam and Treatment Action Group (TAG) -- viewed the workshop as having provided a new forum for health and trade experts to come together on eliminating trade barriers to long-term affordable drug-prices, but expressed their deep disappointment that no progress had been made in bringing the prices down.
The WHO-WTO consideration of the issues, and their convoking the expert meeting itself, is a response to the growing campaign of public interest non-governmental organizations of the North and the South, about the mounting evidence of a runaway global monopoly intellectual property system in the WTO, curbing the rights of national governments, but without countervailing international state power or resources to offset the welfare losses of the poor.
While the campaign of the civil society have raised issues of the legitimacy and locale within the trade system of the WTO’s Trade-Related Intellectual Property Rights (TRIPs) Agreement, the workshop addressed only a narrow range of issues relating to the cost of medicines for the ‘poor countries’, and in terms of ‘differential pricing’ for different users and consumers and how to achieve it, and the issue of financing of medicines (for health care) in these countries.
Trade diplomats (though not often in public) and observers from the Third World view the WTO secretariat, and more so its TRIPs division, as biassed towards the interests of the developed, and corporate interests.
According to the WTO and WHO press releases before the conference, the purpose of the conference was to discuss ‘differential pricing and financing’ of essential drugs—in effect focussing it on the parameters acceptable to the half-dozen transnational pharmaceutical firms and their global monopolies.
The WTO secretariat’s background note written for the meeting (see SUNS #4873 for analysis) - differential pricing and how to achieve it, including by restrictions to prevent ‘leakage’ of products from low-priced to high-priced markets - reflected the approach of the drug companies, and inevitably led to discussions, about which the NGOs have complained.
The meeting was held, in relative isolation from the critical media or others, at Hosbjor in Norway, with a final press conference on a telephone hook-up connecting about a dozen centres in North America and Europe, with seven participants including a representative of the MSF, but none from a developing country.
The telephone hook-up itself was technically so bad that often the questions and answers were difficult to follow and in any event left little scope for questions from those who had familiarity with the trade rules.
As the joint NGO statement at the end of the workshop put it, the workshop had been held to discuss “whether” differential pricing of essential drugs “could” be used as a tool to expand access in developing countries while preserving incentives for future drug development.
Differential pricing, the NGOs felt, could be a crucial tool to help broaden access to affordable medicines in developing countries, but such a mechanism “cannot come with onerous conditions attached, such as forcing poor countries to surrender their rights guaranteed under the TRIPs Agreement.”
The NGO statement said: “After 2-1/2 days of discussion, not a single company disclosed plans to actually implement differential pricing for their drugs. Current offers for AIDS drugs are ad hoc, inadequate, and still far below the prices that can be obtained from generic manufacturers.”
Added the statement, quoting Jamie Love of the CPI: “It is ironic that in a meeting organized to help, the poor, the main drug company proposals were to increase intellectual property protection and ask for the elimination of national price controls. At one point, Oxfam actually offered to give the industry a grant, since they were pleading poverty.”
Besides the World Health Organization and the World Trade Organization who sponsored this meeting (and will be reporting on it respectively to the forthcoming World Health Assembly in May and the WTO’s TRIPs Council in June), two other sponsors were the US based ‘Global Health Council’ - which the WTO has described in its press release as a ‘broad-based US organization in the healthcare field’ and the Norwegian government that hosted the meeting. The WTO said that some 80 experts participated. The list showed that there were some 59 (from academia, industry, some governments, health care groups and NGOs). The rest were officials from the WHO, WTO, the Global Health Council and the Norwegian government.
At the end of the workshop, the WHO Director-General, Dr. Gro Harlem Brundtland and the Director of the WTO secretariat division dealing with TRIPs, Mr. Adrian Otten, summed up in closing remarks their own personal (and organizational) assessments and perhaps, outlooks.
Mrs. Brundtland spoke of the issues addressed at the workshop as ‘essentially political, requiring political solutions, through political processes.”
“We need to be sure we have all the evidence that is available, but there are no technical right answers to most of the things we have been discussing,” she added.
Mr. Otten felt encouraged by what he viewed as “a large measure of common feeling among participants” on the central issues of differential pricing and financing.
In Otten’s view, the large measure of common feeling that emerged on these two were:
· firstly, differential pricing could and should play an important role in ensuring access to existing essential drugs at affordable prices, especially in the poorest countries, while allowing the patent system to continue to play its role of providing incentives for R&D into new drugs;
· secondly, it seemed that there is a general view that, while affordable prices are important, actually getting drugs, whether patented or generic, to the people who need them in poorest countries will require a major financing effort, both to buy the drugs and to reinforce health care supply systems, and that, for these countries, most of the additional financing will have to come from the international community.”
For the NGOs present at the meeting, according to their statement, “one proven effective way to bring prices down is to increase competition by encouraging generic competition.”
Mr. Otten’s statement at the end, also said that there had been “a fair amount of discussion” about the TRIPs Agreement and this showed “a recognition of the importance of respecting the balance that was found in the negotiations” on the agreement and the right of developing countries to use the flexibility in it to respond to health concerns. The focus of much of this discussion, according to him, was how developing countries were able to effectively take advantage of the flexibility for health purposes.
The WTO official added that “there seemed to be wide acceptance of the view that the patent system, while a necessary condition for much R&D, was not a sufficient one to secure adequate R&D into neglected diseases of the poor, and that it needs, to be supplemented with additional measures of support.”
The discussion on ways to make differential pricing effective, and the options that came up ranged from “creating the right conditions and leaving it to the market through bilateral negotiated discounts and the use of non-exclusive voluntary licences, to global procurement and distribution systems.”
And Mr. Otten hastened to add: “Certainly, no conclusion was reached as to the respective pros and cons of these or other options... but we all came out with a better understanding of the options, and there seemed to be a view that it might be necessary for more than one of them to be used, depending on the circumstances.”
Among the points, listed by Otten, relating to the views on these options were:
· making drugs available to the poorest at a price as close as possible to the marginal cost of production, or even lower under donations or where incentives are provided, but questions were raised as to how this price should be determined and reached.
· as for how intermediate or middle income countries should be treated in this regard, the view was expressed that the intermediate countries should pay a price proportionate to their level of income.
· another issue touched upon, but not explored in depth, was how the well-to-do segments in developing countries should be treated, and whether it would be feasible to separate their markets from those of the poor in those countries.
According to Otten, there was also a general view that the diversion of preferentially priced products from those for whom they are intended to markets of Europe, North America and Japan should and can be avoided.
There were many issues raised on these which he thought needed further study - marketing strategies, control of distribution chain by purchasing entity, role of regulatory authorities in developed countries to prevent imports of products produced under a voluntary license, export controls to prevent parallel imports.
Judged by the NGO statement, clearly the views and points that the WTO official discussed as having emerged have not been shared by the public interest NGOs.
Their statement said that in their view “one proven effective way to bring prices down is to increase competition by encouraging generic competition.”
On the differential pricing, the NGOs said that they felt it could be a crucial tool to help broaden access to affordable medicines in developing countries, but that “differential pricing cannot come with onerous conditions attached, such as forcing the poor countries to surrender their rights guaranteed under the TRIPs agreement.”
“Besides differential pricing,” said the NGOs, “other tools - such as voluntary licensing, compulsory licensing, and parallel importing - are available to help broader access to affordable medicines.”
In their statement on the way forward for ‘global access to essential medicines’, the NGOs said they had made a series of recommendations to enhance research and development (R&D) and to ensure that intellectual property right protection serves public health needs rather than the reverse.
“There is no single solution,” the NGOs said, “rather a mix of mutually supportive strategies will be required to assure dramatically reduced drug prices in developing countries.”
And policies to achieve this goal, they said, should be sustainable and not be solely based on charity or donations, and should strengthen the autonomy of developing countries.
The policies should attract donor funding and include all essential medicines and not be limited to drugs for HIV/AIDS and related conditions only.
Only greater competitiveness would help lower drug prices, the NGOs said.
At the meeting, they said, Ellen ‘t Hoen for the MSF suggested:
· equity pricing strategies should not depend solely on voluntary offers by the multinational drug firms.
“Hitherto, most drug companies have preferred low-volume-high-price strategies. Equity or differential pricing should be combined with mechanisms to increase competition and encourage sustainable approaches. For example, it should not have a negative effect on the development of a generic industry in the South.”
The MSF representative told the meeting that one proven effective way to decrease drug prices was to increase competition. In Brazil prices of certain anti-retroviral, anti-HIV drugs came down by 82% within five years after Brazil initiated local production and provided universal free HIV treatment to Brazilian who needed it.
[The US has challenged the Brazilian law providing/requiring local production for patents, and has raised a dispute on it at the WTO]
And recent offers from generic producers, MSF said, have sparked a price war for anti-retrovirals and have brought the annual price for triple therapy down from $10,000 to $350 in a single year.
The need for competitive markets will require flexibility in implementation and a pro public health interpretation of the TRIPs Agreement, the NGOs said and welcomed the special TRIPs Council meeting as proposed by a group of African countries and which will take place in June 2001.
Global procurement strategies and funding should include measures to increase and upgrade generic production in the South. Voluntary licensing and compulsory licensing could help increase the number of generic producers in the market. Voluntary licensing agreements had the added advantage that they would effectively deal with fear of companies that low-priced drugs in developing countries might flow back into high-income country markets.
Calling for a new global Convention on R&D, designed to strengthen both public and private sector research, the NGOs said: “At every gathering to discuss access to medicines, the big pharma companies raise the specter that any effort to help the poor will harm R&D. Some claim proposals to lower drug prices in developing countries, including use of compulsory licensing on essential medicines, may lower their profits. The big pharma solution to R&D is to provide high levels of protection and high prices. But the idea behind a global convention is to create a new mechanism to boost global R&D funding in ways consistent with access to medicines and health needs by encouraging research on neglected diseases. Country support for R&D funding could take a variety of ways, including publicly funded R&D, mandatory R&D requirements for companies.”
The NGOs said they will ask the World Health Assembly in May to request the WHO to convene the negotiations by the end of 2001. – SUNS4876
The above article first appeared in the South-North Development Monitor (SUNS) of which Chakravarthi Raghavan is the Chief Editor.
[c] 2001, SUNS - All rights reserved. May not be reproduced, reprinted or posted to any system or service without specific permission from SUNS. This limitation includes incorporation into a database, distribution via Usenet News, bulletin board systems, mailing lists, print media or broadcast. For information about reproduction or multi-user subscriptions please contact: email@example.com